A carregar...
Development and Use of the Anti-CD19 Chimeric Antigen Receptor T-Cell Therapy Axicabtagene Ciloleucel in Large B-Cell Lymphoma: A Review
IMPORTANCE: Axicabtagene ciloleucel, an anti-CD19-CD28-CD3ζ chimeric antigen receptor T-cell therapy, was the first US Food and Drug Administration–approved, genetically engineered T-cell therapy for adults with relapsed or refractory large B-cell lymphoma (LBCL) after 2 or more lines of systemic th...
Na minha lista:
| Publicado no: | JAMA Oncol |
|---|---|
| Main Authors: | , , |
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado em: |
2020
|
| Assuntos: | |
| Acesso em linha: | https://ncbi.nlm.nih.gov/pmc/articles/PMC7859915/ https://ncbi.nlm.nih.gov/pubmed/31697310 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1001/jamaoncol.2019.3869 |
| Tags: |
Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!
|